Abstract: In the past decades, the advent of molecular targeted agents has been a considerable breakthrough for cancer patients, except for traditional operation, chemotherapy, and radiotherapy. As a novel therapeutic method, molecular targeting treatment is important in the field of medical oncology, in which epidermal growth factor receptor inhibitors (EGFRIs) have been widely used as targeted agents. Dermatological toxicities are the common side effects associated with the EGFRIs. Diarrhea, weakness, and pneumonia can be observed. EGFRI-induced dermatological toxicities may disrupt the health-related quality of life and cause anticancer treatment dose adjustments or discontinuance. The dermatological toxicities mainly involve rash acneiform, pruritus, xerosis, paronychia, hair change, and skin hypersensitivity. Treatment recommendations from guidelines include antibiotics, corticosteroids, and antihistamines, but their clinical therapeutic efficacy have not been proven. Therefore, oncologists and dermatologists are investigating effective medication. This article reviews the advances in the study of the clinical manifestations and drug therapies of EGFRI-induced dermatological toxicities to provide reference for clinical practitioners.